The company's lead program is a monoclonal antibody that targets an immune checkpoint to render tumors susceptible to the body's immune system. BliNK Biomedical's other programs address unique immuno-oncology and immune-checkpoint targets, with the potential to be the next generation of anti-tumor therapeutics. The company's B cell technology allows for efficient and deep mining of antibody-producing cells for difficult targets from various species, aiding in the identification of unique therapeutic antibodies.